Teva Pharmaceutical Industries (TEVJF) Non-Current Debt (2016 - 2025)
Historic Non-Current Debt for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to $15.0 billion.
- Teva Pharmaceutical Industries' Non-Current Debt fell 634.92% to $15.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $15.0 billion, marking a year-over-year decrease of 634.92%. This contributed to the annual value of $15.0 billion for FY2025, which is 634.92% down from last year.
- Teva Pharmaceutical Industries' Non-Current Debt amounted to $15.0 billion in Q4 2025, which was down 634.92% from $16.8 billion recorded in Q3 2025.
- In the past 5 years, Teva Pharmaceutical Industries' Non-Current Debt registered a high of $22.3 billion during Q1 2021, and its lowest value of $15.0 billion during Q4 2025.
- Moreover, its 5-year median value for Non-Current Debt was $18.5 billion (2022), whereas its average is $18.5 billion.
- As far as peak fluctuations go, Teva Pharmaceutical Industries' Non-Current Debt plummeted by 1568.03% in 2024, and later soared by 223.17% in 2025.
- Over the past 5 years, Teva Pharmaceutical Industries' Non-Current Debt (Quarter) stood at $21.6 billion in 2021, then dropped by 11.63% to $19.1 billion in 2022, then dropped by 4.93% to $18.2 billion in 2023, then decreased by 11.89% to $16.0 billion in 2024, then fell by 6.35% to $15.0 billion in 2025.
- Its Non-Current Debt was $15.0 billion in Q4 2025, compared to $16.8 billion in Q3 2025 and $16.8 billion in Q2 2025.